 | Up a level |
Kanis, J A; Johansson, H; McCloskey, E V; Liu, E; Åkesson, K E; Anderson, F A; Azagra, R; Bager, C L; Beaudart, C; Bischoff-Ferrari, H A; Biver, E; Bruyère, O; Cauley, J A; Center, J R; Chapurlat, R; Christiansen, C; Cooper, C; Crandall, C J; Cummings, S R; da Silva, J A P; ... (2023). Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX. Osteoporosis international, 34(12), pp. 2027-2045. Springer-Verlag 10.1007/s00198-023-06870-z
Vandenput, L; Johansson, H; McCloskey, E V; Liu, E; Åkesson, K E; Anderson, F A; Azagra, R; Bager, C L; Beaudart, C; Bischoff-Ferrari, H A; Biver, E; Bruyère, O; Cauley, J A; Center, J R; Chapurlat, R; Christiansen, C; Cooper, C; Crandall, C J; Cummings, S R; da Silva, J A P; ... (2022). Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan. Osteoporosis international, 33(10), pp. 2103-2136. Springer-Verlag 10.1007/s00198-022-06435-6
Boonen, S; Adachi, J D; Man, Z; Cummings, S R; Lippuner, K; Törring, O; Gallagher, J C; Farrerons, J; Wang, A; Franchimont, N; San Martin, J; Grauer, A; McClung, M (2011). Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. Journal of clinical endocrinology and metabolism, 96(6), pp. 1727-36. Chevy Chase, Md.: Endocrine Society 10.1210/jc.2010-2784
